In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

GW Pharmaceuticals plc

https://www.gwpharm.com

Latest From GW Pharmaceuticals plc

GW Pharma Among Myriad Hopefuls Seeking Extended Indications In EU

Applications to widen the therapeutic indications of up to 20 approved drugs will be decided on this week at the European Medicines Agency.

Drug Review Europe

Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Coronavirus COVID-19

Zogenix Risks Fintepla Uptake With Dravet Drug’s High Price

The average list price of $96,000 per year is three times the cost of GW’s competing drug Epidiolex, but Zogenix is betting that the reduction in seizures seen in clinical trials will justify the expense. 

Launches Pricing Strategies

UK Eases Access To GW's Cannabidiol Epilepsy Drug

The easing of the regulations governing GW Pharmaceuticals’ groundbreaking epilepsy drug in the UK will be followed by wider availability in Europe as pricing and reimbursement discussions continue.

United Kingdom United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Greenwich Biosciences, Inc.
UsernamePublicRestriction

Register